A phase 3 trial across France, Germany, and the UK evaluated the monoclonal antibody nirsevimab in 8,057 infants under 12 months, finding an 82.7% reduction in hospitalizations due to RSV-associated lower respiratory tract infections. Nirsevimab demonstrated 75.3% effectiveness against severe RSV-associated LRTI and 41.9% for all-cause LRTIs. Consistent efficacy was noted across diverse age and weight categories, with no new safety concerns reported. The study indicates nirsevimab can offer prolonged protection, aligning with well-baby visit schedules.

Source: The Lancet Child & Adolescent Health